logo
Pre-IPO Anduril Now Worth $30 Billion

Pre-IPO Anduril Now Worth $30 Billion

Yahoo3 hours ago

Unicorn defense and AI stock Anduril hit its first $1 billion valuation six years ago.
Today, Anduril is making $1 billion a year in revenue, its privately-owned stock has gone up 30-fold, and it wants to IPO.
Anduril's a popular defense stock, but it costs far too much to justify buying.
These 10 stocks could mint the next wave of millionaires ›
Once upon a time, unicorn companies -- privately owned, but valued in excess of $1 billion -- were a rare breed. Lately, there seem to be whole herds of them.
Take Anduril for example. The privately held artificial intelligence and defense company founded by Oculus VR inventor Palmer Luckey first hit the magic $1 billion private market value back in 2019. But Anduril didn't stop there. Growing steadily over the past half-decade, the privately traded defense stock last week raised $2.5 billion in new cash, and the company as a whole is now valued at $30.5 billion, according to a report from Bloomberg.
That's a growth rate any investor would love to get a piece of. And while you cannot invest in Anduril stock yet, you might soon be able to.
Because Anduril says it's going to IPO.
Anduril Chairman Trae Stephens told Bloomberg his company aims to "scale into the largest problems for the national security community." Of particular note, Anduril recently took over a gigantic $22 billion Pentagon augmented reality contract from Microsoft. But Anduril needs cash to reach the scale it wants "to shore up the balance sheet and make sure we have the ability to deploy capital into these manufacturing and production problem sets that we're working on."
Pre-IPO companies like Anduril have three ways they can do that. They can take out loans (at currently high interest rates). Or they can hold an IPO and sell their shares to public investors for cash. Or they can sell shares discretely, in a private stock offering. This last route is the one Anduril took, but in his interview with Bloomberg, Stephens made it clear he's not ruling out an IPO -- at all.
"Long term we continue to believe that Anduril is the shape of a publicly traded company," said Stephens. "We're not in any rapid path to doing that [but] we're certainly going through the processes required to prepare for doing something like that in the medium term."
Stephens and Luckey might want to shift that focus into the short term, however, because circumstances may never be better to make Anduril a popular IPO stock. It's been only a couple of weeks now since Ukraine launched Operation Spiderweb, deploying more than 100 artificial intelligence (AI)-guided drones from trucks to attack airfields across Russia, causing billions of dollars' worth of damage to military assets -- apparently with no casualties -- for an investment measured in thousands of dollars.
The memory of that mission hadn't even faded before Israel launched its own surprise attack on Iran, Operation Rising Lion, last week. While most headlines focus on the exploits of Israel's hundreds of fighter aircraft bombing military and nuclear targets in Iran, Israel's Mossad spy agency apparently also used drones and remotely operated weapons systems to great effect.
These attacks weren't just reminiscent of Operation Spiderweb. They were reminiscent of Anduril's own artificial intelligence drone technology. With both successes fresh in investors' minds right now, there may be no better time to launch an IPO to capitalize on this free publicity.
But let's not get irrationally exuberant here. What's good for Anduril isn't necessarily good for investors. As popular a stock as Anduril might be if it IPOs, that doesn't necessarily mean you should buy it.
Consider what a $30.5 billion valuation means for a future publicly traded Anduril stock.
According to Luckey, Anduril roughly doubled its 2023 revenue in 2024, making "about a billion" dollars in 2024 sales. The company isn't believed to be profitable yet, so that doesn't mean much in terms of P/E ratios. But it does mean that Anduril sells for a price-to-sales ratio of about 30.5.
Compare that to alternatives in the "new defense tech" space. AeroVironment (NASDAQ: AVAV), which up until about the time of Russia's 2022 invasion of Ukraine was the biggest name in U.S. drone stocks, costs 7.4 times trailing sales -- one quarter of Anduril's valuation. And AeroVironment is a profitable defense stock, earning about $33 million last year.
Karman Holdings (NYSE: KRMN), itself a recent defense stock IPO (that I've argued is also overpriced) is closer to Anduril's valuation at 17.3 times sales, but still only about half as expensive. And again, Karman is already earning profits.
Don't even ask about more traditional defense contractors like General Dynamics, Lockheed Martin, or Northrop Grumman. Combined, those three giants earned more than $13 billion last year, but their P/S ratios range from only 1.6 (GD and Lockheed) to 1.9 times sales. That's way cheaper than any of the new defense tech stocks, Anduril included, and with far longer track records of success.
I'm not here to knock Anduril. As a company, I think it's pretty great, and a superb success story in American business. I have high (if cautious) hopes that Anduril might shake up an entrenched and overly concentrated defense industry that's basically made up of companies like General D, LockMart, and Northrop, and help the Pentagon to spend taxpayer defense dollars more wisely.
I just don't think you should invest in Anduril stock. Not at today's valuation, at least.
Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this.
On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves:
Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $377,293!*
Apple: if you invested $1,000 when we doubled down in 2008, you'd have $37,319!*
Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $659,171!*
Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of June 9, 2025
Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AeroVironment and Microsoft. The Motley Fool recommends Lockheed Martin and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Pre-IPO Anduril Now Worth $30 Billion was originally published by The Motley Fool

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Universal Health Services, Inc.'s (NYSE:UHS) Intrinsic Value Is Potentially 34% Above Its Share Price
Universal Health Services, Inc.'s (NYSE:UHS) Intrinsic Value Is Potentially 34% Above Its Share Price

Yahoo

time29 minutes ago

  • Yahoo

Universal Health Services, Inc.'s (NYSE:UHS) Intrinsic Value Is Potentially 34% Above Its Share Price

Universal Health Services' estimated fair value is US$229 based on 2 Stage Free Cash Flow to Equity Universal Health Services is estimated to be 25% undervalued based on current share price of US$172 Our fair value estimate is 1.8% higher than Universal Health Services' analyst price target of US$225 In this article we are going to estimate the intrinsic value of Universal Health Services, Inc. (NYSE:UHS) by taking the expected future cash flows and discounting them to their present value. We will use the Discounted Cash Flow (DCF) model on this occasion. There's really not all that much to it, even though it might appear quite complex. Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we need to discount the sum of these future cash flows to arrive at a present value estimate: 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 Levered FCF ($, Millions) US$1.06b US$1.19b US$686.5m US$628.6m US$597.1m US$581.4m US$575.8m US$577.0m US$582.9m US$592.3m Growth Rate Estimate Source Analyst x1 Analyst x3 Analyst x2 Est @ -8.43% Est @ -5.02% Est @ -2.63% Est @ -0.96% Est @ 0.21% Est @ 1.03% Est @ 1.60% Present Value ($, Millions) Discounted @ 6.4% US$997 US$1.1k US$570 US$490 US$438 US$401 US$373 US$351 US$333 US$318 ("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = US$5.3b The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.9%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 6.4%. Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = US$592m× (1 + 2.9%) ÷ (6.4%– 2.9%) = US$18b Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$18b÷ ( 1 + 6.4%)10= US$9.5b The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is US$15b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of US$172, the company appears a touch undervalued at a 25% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind. We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Universal Health Services as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.4%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. See our latest analysis for Universal Health Services Strength Earnings growth over the past year exceeded the industry. Debt is well covered by earnings and cashflows. Weakness Dividend is low compared to the top 25% of dividend payers in the Healthcare market. Opportunity Annual earnings are forecast to grow for the next 3 years. Good value based on P/E ratio and estimated fair value. Threat Annual earnings are forecast to grow slower than the American market. Valuation is only one side of the coin in terms of building your investment thesis, and it shouldn't be the only metric you look at when researching a company. The DCF model is not a perfect stock valuation tool. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. Can we work out why the company is trading at a discount to intrinsic value? For Universal Health Services, we've put together three essential factors you should explore: Risks: For example, we've discovered 1 warning sign for Universal Health Services that you should be aware of before investing here. Future Earnings: How does UHS's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered! PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the NYSE every day. If you want to find the calculation for other stocks just search here. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio

Investors in Cogeco Communications (TSE:CCA) have seen decent returns of 40% over the past year
Investors in Cogeco Communications (TSE:CCA) have seen decent returns of 40% over the past year

Yahoo

time29 minutes ago

  • Yahoo

Investors in Cogeco Communications (TSE:CCA) have seen decent returns of 40% over the past year

Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost returns by picking market-beating companies to own shares in. To wit, the Cogeco Communications Inc. (TSE:CCA) share price is 32% higher than it was a year ago, much better than the market return of around 19% (not including dividends) in the same period. So that should have shareholders smiling. Unfortunately the longer term returns are not so good, with the stock falling 24% in the last three years. Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. Over the last twelve months, Cogeco Communications actually shrank its EPS by 6.6%. So we don't think that investors are paying too much attention to EPS. Therefore, it seems likely that investors are putting more weight on metrics other than EPS, at the moment. Absent any improvement, we don't think a thirst for dividends is pushing up the Cogeco Communications' share price. We don't find the recent revenue growth particularly impressive at a glance, but shareholders could be projecting an uptick. You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values). We consider it positive that insiders have made significant purchases in the last year. Even so, future earnings will be far more important to whether current shareholders make money. This free report showing analyst forecasts should help you form a view on Cogeco Communications It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. We note that for Cogeco Communications the TSR over the last 1 year was 40%, which is better than the share price return mentioned above. And there's no prize for guessing that the dividend payments largely explain the divergence! It's nice to see that Cogeco Communications shareholders have received a total shareholder return of 40% over the last year. Of course, that includes the dividend. Notably the five-year annualised TSR loss of 3% per year compares very unfavourably with the recent share price performance. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. It's always interesting to track share price performance over the longer term. But to understand Cogeco Communications better, we need to consider many other factors. For example, we've discovered 1 warning sign for Cogeco Communications that you should be aware of before investing here. Cogeco Communications is not the only stock insiders are buying. So take a peek at this free list of small cap companies at attractive valuations which insiders have been buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Canadian exchanges. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Retail investors account for 55% of Gesher Acquisition Corp. II's (NASDAQ:GSHR) ownership, while private companies account for 29%
Retail investors account for 55% of Gesher Acquisition Corp. II's (NASDAQ:GSHR) ownership, while private companies account for 29%

Yahoo

time33 minutes ago

  • Yahoo

Retail investors account for 55% of Gesher Acquisition Corp. II's (NASDAQ:GSHR) ownership, while private companies account for 29%

Significant control over Gesher Acquisition II by retail investors implies that the general public has more power to influence management and governance-related decisions 45% of the business is held by the top 5 shareholders 11% of Gesher Acquisition II is held by Institutions This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. If you want to know who really controls Gesher Acquisition Corp. II (NASDAQ:GSHR), then you'll have to look at the makeup of its share registry. With 55% stake, retail investors possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk). Private companies, on the other hand, account for 29% of the company's stockholders. Let's take a closer look to see what the different types of shareholders can tell us about Gesher Acquisition II. View our latest analysis for Gesher Acquisition II Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. We can see that Gesher Acquisition II does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Gesher Acquisition II's earnings history below. Of course, the future is what really matters. It would appear that 5.3% of Gesher Acquisition II shares are controlled by hedge funds. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. Gesher Acquisition Sponsor II LLC is currently the company's largest shareholder with 29% of shares outstanding. For context, the second largest shareholder holds about 5.3% of the shares outstanding, followed by an ownership of 4.7% by the third-largest shareholder. Our studies suggest that the top 5 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder. While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our data cannot confirm that board members are holding shares personally. Given we are not picking up on insider ownership, we may have missing data. Therefore, it would be interesting to assess the CEO compensation and tenure, here. The general public, mostly comprising of individual investors, collectively holds 55% of Gesher Acquisition II shares. With this amount of ownership, retail investors can collectively play a role in decisions that affect shareholder returns, such as dividend policies and the appointment of directors. They can also exercise the power to vote on acquisitions or mergers that may not improve profitability. It seems that Private Companies own 29%, of the Gesher Acquisition II stock. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company. I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Like risks, for instance. Every company has them, and we've spotted 3 warning signs for Gesher Acquisition II (of which 2 are concerning!) you should know about. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store